证券代码：华大基因 证券简称：300676 深圳华大基因股份有限公司投资者关系活动记录表 编号：2025-007 | 投 资 | 者 | 关 系 | □特定对象调研 □分析师会议 | | --- | --- | --- | --- | | 活动类别 | | | □媒体采访 √业绩说明会 | | | | | □新闻发布会 □路演活动 | | | | | □现场参观 √其他（电话交流会） | | 参 与 称 及 | 单 人 | 位 名 员 姓 | 国联证券：林艾灵；中信证券：李文涛；兴业证券：龚涵清；浙商证券：司 清蕊；西南证券：陈辰；中天汇富基金：古道和；金信基金：黄彪；创金合 | | | | | 信：周志敏；诺安基金：王晴；中融基金：刘博川等 80 人。 | | 名 | | | | | 时间 | | 2025 | 年 月 日 8 25 15:00-16:00 | | 地点 | | | 广东省深圳市盐田区云华路 号 华大时空中心会议室 9 | | 上 市 | 公 | 总经理 司 接 | 赵立见；医学业务负责人 侯勇；副总经理 李宁；副总经理 朱师达； | | | | | 副总经理、财务总监 王玉珏；副总经理、董 ...

｜广告｜ 动说明。 名医访谈 健康守护 敬 请 期 待 都 喜因梭测与健康管理新时代 看懂你的基因说明书 王峰 教授 · 暨南大学祈福医院 主任医师 · 复美国际精准医疗中心 高级临床专家 ·澳门大学生命科学院 客座教授 适合群体 全年龄,特别是关注健康管理和有慢病家族史的人 简要介绍 介绍人类基因到检测技术的演变,从慢性病、肿瘤、药物 代谢、到个性化健康管理,哪些风险可以提前预知,以及 该对生活方式如何干预。 "未病先防",如何躲过慢性病第一刀 慢性病从不突然发作，而是从没被发现开始 电维玺 博士 适合群体 毕伟 教授 博士生导师 · 暨南大学附属第一医院 神经内科主任 (国家临床重点专科) 日完尔 十三四六开出左右兰之边纪念 30-60岁,压力大、饮食作息不规律、家族慢性病史,高净 值人群、白领、企业主和关注父母健康的人。 简要介绍 紧扣"未病先防"，通过慢性病、三高、家族心血管史, 讲解基因检测的实际应用, "今天一次检测，可能省掉未 来大笔治疗支出"。 第三期 身体的"隐形年龄",你的基因暴露了 3 U > 174 22 别让身体偷偷变老 · 深圳市人民医院 肿瘤内科主任 · 深圳市抗癌协会理事长 · ...

Core Viewpoint - Berry Genomics (000710.SZ) announced the establishment of a joint venture, Henan Yiyuan Tongkang Gene Technology Co., Ltd., in Zhengzhou, Henan Province, focusing on integrated genetic testing services for newborns and children [1] Group 1: Joint Venture Details - The joint venture will be co-funded by Berry Genomics' wholly-owned subsidiary, Berry Health, which will contribute 600,000 yuan (60% ownership), while individual investor Li Wei will contribute 400,000 yuan (40% ownership) [1] - The registered capital of the joint venture is set at 1 million yuan, primarily allocated for venue rental and initial personnel costs [1] Group 2: Business Operations - The joint venture aims to collaborate closely with public medical institutions and clinical medical enterprises in key regions such as Henan to provide genetic disease testing services [1] - Products and related services, including gene sequencing and AI intelligent services, will primarily be procured from Chengdu Berry Health Gene Technology Co., Ltd. and its subsidiaries [1] Group 3: Future Capital Plans - The joint venture plans to increase its registered capital to no less than 50 million yuan, depending on business progress and operational performance [1]

Core Viewpoint - Berry Genomics (000710.SZ) announced the establishment of a joint venture, Henan Yiyuan Tongkang Gene Technology Co., Ltd., with individual investor Li Wei, focusing on integrated genetic testing services for newborns and children in key regions like Henan [1] Group 1: Joint Venture Details - The joint venture will have a registered capital of 1 million yuan, with Berry and Kang contributing 600,000 yuan (60% ownership) and Li Wei contributing 400,000 yuan (40% ownership) [1] - The joint venture aims to collaborate closely with public medical institutions and clinical medical enterprises [1] Group 2: Funding and Operations - Initial funding will be allocated for rent and personnel costs, with products and services, including gene sequencing and AI intelligent services, sourced from Berry and Kang and its subsidiaries [1] - The joint venture plans to increase its registered capital to no less than 50 million yuan based on business progress and expectations [1]

Core Insights - GeneDx Holdings Corp. reported a significant turnaround in Q2 2025 with adjusted diluted EPS of 50 cents, compared to a loss of 8 cents per share in the same period last year, exceeding estimates by 400% [1][8] - Total revenues for the quarter increased by 45.6% year over year to $102.7 million, surpassing the Zacks Consensus Estimate by 21.2% [2][9] - The company achieved a gross profit of $70.9 million, reflecting a 65.1% year-over-year increase, with gross margin expanding by 813 basis points to 69% [3][9] Revenue Performance - Exome and genome test revenues grew by 69% year over year, reaching $85.9 million [2][9] - The company crossed the $100 million revenue mark for the first time, marking a significant milestone [9] Expense and Profitability Metrics - Adjusted total operating expenses were $61.9 million, an increase of 15.7% year over year, leading to an operating profit of $9 million compared to an operating loss of $10.6 million in the previous year [4][9] - Selling and marketing expenses rose by 17.3% to $19.4 million, while general and administrative expenses increased by 5.3% to $27.4 million [3] Cash Position - At the end of Q2 2025, GeneDx had cash, cash equivalents, and marketable securities totaling $134.6 million, down from $159.2 million at the end of Q1 2025 [5] Future Outlook - The company raised its full-year 2025 sales guidance to a range of $400-$415 million from the previous $360-$375 million, with the Zacks Consensus Estimate currently at $371.3 million [6] - Adjusted net income for the year is expected to be positive, with earnings estimated at $1.13 per share [6] Strategic Developments - During the quarter, GeneDx advanced its growth strategy by acquiring Fabric Genomics, which supports a hybrid model for delivering genomic insights globally [10] - The company also expanded its commercial focus to include inborn errors of immunity as a new indication for its genetic testing [10]

Core Insights - BGI Genomics is facing significant challenges, including declining revenues, substantial losses, and increased market competition, which threaten its position in the gene sequencing industry [1][2][10]. Financial Performance - In 2024, BGI Genomics reported revenue of 3.867 billion yuan, a year-on-year decline of 11.10%, and a net loss of 903 million yuan, marking the first annual net loss since its IPO, with a staggering decline of 1071.68% [2]. - For Q1 2025, the company’s revenue was 672 million yuan, down 18.18% year-on-year, with a net loss of 52.7 million yuan, a decline of 524.87% [3]. - The reproductive health segment generated 1.149 billion yuan in 2024, a slight decline of 2.46%, while the oncology and chronic disease prevention segment saw revenue growth of 19.02%, reaching 625 million yuan [5]. - The infectious disease prevention segment suffered a dramatic decline, with revenue of only 73 million yuan, down 85.91%, primarily due to reduced demand from public health events and stricter regulations [5]. - Asset impairment losses reached 242 million yuan in 2024, exacerbated by high R&D costs and increased operational expenses [6]. Market Dynamics - BGI Genomics' stock price has experienced a cumulative decline of 79.13% since its peak in November 2017, with a market capitalization reduction of over 80 billion yuan, leaving it at 22.116 billion yuan by July 2025 [8]. - The company’s profitability has been questioned due to unstable earnings, leading to diminished investor confidence amid intensified competition and emerging technologies [8][10]. - The gene sequencing industry is witnessing fierce competition, with new entrants and established players enhancing their technological capabilities, which poses a direct threat to BGI Genomics [10][12]. - Price competition is intensifying, particularly after the inclusion of NIPT in volume-based procurement, which has significantly reduced product prices and profit margins [13]. Strategic Challenges - BGI Genomics must navigate a complex regulatory environment that affects its operations, particularly in the infectious disease sector, where new policies have severely impacted its market space [13][14]. - The company faces challenges in international markets due to legal and regulatory uncertainties, as well as competitive disadvantages against established global players [14]. - To overcome its current challenges, BGI Genomics needs to optimize its business structure, enhance innovation capabilities, control costs, and improve market strategies [14][15].

Business Overview - CareDx is focused on a $6B+ market opportunity in transplant care[20, 29] - The company's mission is to improve long-term outcomes by providing innovative solutions throughout the entire transplant patient journey[19] - Over 70% of organ transplant centers use one or more of CareDx's digital patient journey solutions[63] Financial Performance - Full year 2023 revenue reached $280.3M, exceeding the high end of updated guidance[77] - Testing Services revenue for 2023 was $209.7M with approximately 165,700 patient results[77] - Patient and Digital Solutions revenue grew by 29% year-over-year to $37.1M in 2023[77] - Product revenue increased by 15% year-over-year to $33.5M in 2023[77] - The company repurchased 2.9 million shares for $27.5 million in 2023[77] - CareDx ended 2023 with approximately $235.4M in cash and marketable securities and no debt[77] Future Outlook - 2024 revenue guidance is set at $260M to $274M[101] - Non-GAAP operating expenses are projected to be between $207M and $215M in 2024[101]

Summary of Amicus Therapeutics (FOLD) FY Conference Call - June 10, 2025 Company Overview - **Company**: Amicus Therapeutics - **Core Business**: Development of therapies for rare diseases, primarily focusing on Galafold for Fabry disease and Pombility for Pompe disease - **Sales Projections**: Expected to surpass $500 million in sales for Galafold and $100 million for Pombility in 2025 [3][4] Key Points and Arguments Financial Performance and Growth - **Galafold**: - Projected to achieve $1 billion in peak sales with a growth rate of 10% to 15% in 2025 [4] - Currently in a $2 billion global market, expected to grow to $3 billion over the next decade [8][9] - **Pompe Disease Therapies**: - Pombility and Upholda projected to achieve $100 million in sales with a growth rate of 50% to 65% [4] - Anticipated to reach $1 billion in sales in the future [4] - **New Asset - DMX200**: - Licensed from Dimerix for FSGS, a rare kidney disease, with potential blockbuster status [5] - Expected to contribute to significant revenue growth by 2028 [5] Market Position and Competitive Landscape - **Macro Environment**: - Company believes it is well-positioned to navigate macroeconomic challenges affecting the sector [7][8] - Emphasizes the undervaluation of Galafold and the potential for increased diagnoses in the Fabry disease space [8][9] - **Launch Dynamics**: - Initial launch delays due to COVID-19 impacted market entry for Pompe therapies [37] - Positive trends observed in the U.S. market with increasing patient switches from competitors [39][41] Regulatory and Operational Considerations - **Impact of Tariffs and Regulations**: - Minimal impact from tariffs due to low cost of goods for Galafold, which is manufactured in Switzerland [16][18] - Company is adapting to regulatory changes and believes it is insulated from potential negative impacts [20][22] - **FDA Dynamics**: - New leadership at the FDA is expected to support rare disease regulatory reforms, potentially benefiting Amicus [23][24] Guidance and Future Outlook - **Profitability Expectations**: - Guidance for GAAP profitability in the second half of 2025, with revenue growth projected at 15% to 22% [25][26] - Operating expenses expected to remain flat or increase slightly, allowing for positive free cash flow [27][29] - **Long-term Strategy**: - Focus on maintaining financial discipline while expanding the product portfolio [6][12] - Plans to leverage cash flow for new development opportunities in rare diseases [80] Additional Important Insights - **Market Dynamics**: - The company is seeing strong uptake in initial launch countries, with market shares reaching 20-30% in key markets [47] - New countries like the Netherlands are expected to significantly contribute to revenue through patient switches [50][52] - **Patient Diagnosis Trends**: - Increased diagnosis rates for Fabry disease due to lower costs of genetic testing and newborn screenings [64][66] - Potential for significant patient population growth as awareness and testing improve [67][70] Conclusion Amicus Therapeutics is positioned for strong growth in the rare disease market, with a focus on financial discipline and strategic expansion. The company anticipates achieving profitability in the near term while navigating macroeconomic challenges and regulatory changes. The potential for increased patient diagnoses and successful product launches underpins a positive outlook for future revenue growth.

Core Viewpoint - The innovative drug Tofersen injection for treating SOD1-ALS has officially launched in China, marking a significant advancement in the treatment of this rare and fatal neurological disease [1][2]. Group 1: Drug and Treatment Details - Tofersen injection is the first disease-modifying treatment for SOD1-ALS, providing a new hope for patients suffering from this condition [1][2]. - The drug is an antisense oligonucleotide (ASO) that reduces the synthesis of the toxic SOD1 protein, thereby alleviating damage to motor neurons and slowing disease progression [2][3]. - The drug was approved in September 2022 for adult patients with SOD1 gene mutations, addressing a significant unmet need in the treatment of ALS [2][3]. Group 2: Patient and Clinical Insights - The average onset age for SOD1-ALS patients is around 50 years, with a typical presentation of lower limb onset and simultaneous damage to upper and lower motor neurons [3]. - There is an urgent demand for targeted therapies among patients due to the fatal nature of the disease [3]. - The importance of genetic testing for all ALS patients, including those with SOD1 mutations, is emphasized for accurate diagnosis and treatment [2][3]. Group 3: Advocacy and Future Directions - Experts call for the standardization of genetic testing and treatment protocols to ensure timely access to this breakthrough therapy for eligible patients [3]. - There is a collective appeal from advocacy groups to raise awareness and improve access to innovative therapies for rare disease populations [3].

Core Insights - 23andMe, a well-known genetic testing company, is experiencing a dramatic turn of events after filing for bankruptcy three months ago, with co-founder Anne Wojcicki proposing a $305 million acquisition bid to restart the bidding process for the company's assets, including customer genetic data [1][3] Company Overview - 23andMe filed for bankruptcy in March 2025 due to declining consumer demand and a data breach incident in 2023 that exposed sensitive genetic and personal information of millions of customers, leading to significant operational challenges [1][3] - The company’s stock price is currently at $3.965, with a market capitalization reduced to $106 million [3] - In the bankruptcy auction phase, Regeneron Pharmaceuticals initially offered $256 million and was selected as the primary bidder, but Wojcicki's non-profit organization, TTAM Research Institute, later made a competing bid [3] Financial Context - Following its merger with VG Acquisition Corp in June 2021, 23andMe raised $509 million in cash and $250 million in PIPE financing, which highlights the company's previous financial strength before its recent struggles [3] Leadership and Influence - Anne Wojcicki, a successful entrepreneur and former wife of Google co-founder Sergey Brin, has been a prominent figure in Silicon Valley, showcasing resilience by continuing to pursue ownership of 23andMe despite the company's challenges [5][6]